PDX Pharmaceuticals LLC, also known as Raksa Therapeutics, is a biopharmaceutical company based in Lake Oswego, Oregon. They specialize in leveraging novel nanotechnology and cancer systems biology to develop next-generation combination immunotherapies for cancer, with a focus on enhancing cancer-specific immunity through their nanotherapeutic pipelines.
Their proprietary nanoparticle platform, Pdx-NPTM, allows for the co-delivery of siRNA, drugs, vaccines, and immunotherapies, enabling targeted delivery to solid tumors and effective in situ tumor vaccination. PDX Pharma is currently conducting IND enabling studies for their drug candidates ARAC-02 and AIRISE-02, both funded by the National Cancer Institute, and aims to complete clinical trials by 2025 with additional private investment.
Generated from the website